微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 39.48% | -4.66% | 5.32% | 93/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 37.49% | -6.83% | 8.94% | 99/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 34.41% | -10.61% | -20.36% | 103/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 43.21% | -10.73% | 4.34% | 92/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 41.41% | -16.17% | 2.91% | 94/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 40.24% | -19.15% | 4.52% | 97/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 38.49% | -24.03% | -20.46% | 99/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 48.4% | -7.6% | -2.03% | 80/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 49.4% | -5.79% | -0.74% | 79/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 49.77% | -5.33% | -1.78% | 81/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 50.67% | 0.35% | -3.26% | 75/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 52.38% | -7.63% | -0.11% | 82/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 52.44% | -8.02% | -0.26% | 75/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 52.57% | -8.52% | 4.12% | 77/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 50.49% | -12.29% | -10.96% | 78/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 56.71% | -3.82% | -0.53% | 70/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 57.01% | -4.01% | -0.8% | 61/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 57.47% | -4.63% | -0.17% | 66/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 57.56% | 3.32% | -2.37% | 58/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 58.96% | 15.08% | -0.73% | 61/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 59.39% | 16.88% | -1.43% | 51/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 60.26% | 20.33% | 8.15% | 51/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 55.72% | 17.29% | 8.74% | 50/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 51.24% | 3.58% | 0.82% | 75/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 50.82% | 4.61% | 1.47% | 61/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 50.08% | 4.61% | 5.42% | 64/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 47.5% | 4.75% | -3.97% | 63/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 49.47% | 6.66% | 1.83% | 72/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.58% | 5.25% | 1.47% | 56/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 47.87% | 9.64% | 5.56% | 61/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 45.35% | 2% | -2.21% | 62/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 46.38% | 10.19% | 0.48% | 71/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 46.15% | 2% | 5.7% | 52/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 43.66% | 2% | 3.75% | 56/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 42.09% | 53.35% | 53.35% | 64/158 | 48.52% | 退市金泰 | 95.93% | 行业排名> |